Phase 2 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Participants must have given written consent to take part in the study.
- Adults aged 18 to 70 years old, of any gender, may be considered.
- People who have been diagnosed (through tissue or cell testing) with a specific type of lung cancer called non-squamous non-small cell lung cancer (such as adenocarcinoma) that has spread to the brain, and who are not suitable for or have declined local treatment or surgery for the brain spread.
- People who have at least one measurable area of cancer in the brain, based on standard medical measurement guidelines (a previously treated area can only count if it has clearly grown after treatment).
- People whose brain metastases are stable and do not need immediate or planned local brain treatment during the study.
- People whose tumour does not have certain gene changes (called driver genes), and who either cannot tolerate standard treatment or whose cancer has progressed during or after a first course of treatment combining platinum-based chemotherapy and immunotherapy, and who have cancer that has spread to the brain (regardless of whether that brain spread has been previously treated).
- People with a good general health status (rated 0 or 1 on a standard scale) and an expected survival of more than 12 weeks.
- People whose blood test results during screening show that bone marrow, kidney, liver, and blood clotting function all meet the specific laboratory requirements set out by the trial (confirm with trial site for exact values).
- People of childbearing potential (male or female) who agree to use reliable contraception during the trial and for at least 3 months after the last dose, and female participants of reproductive age must have a negative pregnancy test before joining.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People with a primary brain tumour, unstable brain metastases with symptoms, or cancer that has spread to the lining around the brain and spinal cord.
- People whose lung cancer has a significant squamous cell component (10% or more squamous cancer cells confirmed by testing).
- People whose previous testing showed the presence of certain gene changes (EGFR, ALK, ROS1, NTRK, or MET driver genes).
- People who had all brain lesions treated with whole-brain or targeted radiation and have not had any disease progression since, meaning there is no measurable lesion remaining.
- People who had a large, uncontrolled build-up of fluid around the heart, lungs, or abdomen in the 4 weeks before joining that could not be managed by draining or other methods.
- People who received palliative radiation to non-target areas for symptom relief (such as for bone pain) within 2 weeks before the first study dose, or who previously had whole-brain radiation therapy unless they had prior targeted radiation or other local brain treatments more than 2 weeks before the first study dose.
- People who previously received certain anti-cancer drugs including anti-angiogenic drugs (such as bevacizumab, recombinant human endostatin, or anlotinib), or who received chemotherapy or immunotherapy within 4 weeks before the first study dose, or certain targeted or traditional Chinese medicines within 2 weeks before the first study dose.
- People who have a known medical reason why they cannot have an MRI scan with gadolinium contrast dye, such as having a pacemaker, metal fragments in the body, or foreign objects in the eyes.
- People who have had two or more seizures in the 4 weeks before joining.
- People with a known allergy to the study drugs (eutideron injection, bevacizumab, or any of their ingredients).
- People who have moderate to severe nerve damage in the hands or feet (grade 2 or higher), significant skin problems requiring treatment, or side effects from previous cancer treatment that have not sufficiently resolved before the first dose (except for mild hair loss).
- People who have certain conditions that make bevacizumab unsafe to use, including: uncontrolled high blood pressure; history of bleeding in the brain; history of significant protein in the urine; history of a severe high blood pressure crisis; history of certain brain or nervous system conditions unrelated to cancer; certain blood vessel conditions such as an aneurysm needing treatment within 6 months before the first dose; history of coughing up significant amounts of blood within 3 months before the first dose; history of bleeding or clotting disorders without therapeutic anticoagulants; cancer involving major blood vessels; or history of a hole or abnormal channel in the digestive system within 6 months before the first dose.
- People who have had another cancer (other than the current one) in the 5 years before screening, with exceptions for certain fully treated early-stage cancers such as cervical carcinoma in situ, certain skin cancers, localised prostate cancer after surgery, breast ductal carcinoma in situ, or papillary thyroid carcinoma.
- People who have had major surgery within 4 weeks before the first study dose, or who have not fully recovered from a previous surgical or invasive procedure.
- People who have used aspirin at high doses, clopidogrel, ticlopidine, cilostazol, or other drugs that affect platelet function, or full-dose blood-thinning medication, within 10 days before the first dose.
- People with active hepatitis B, active hepatitis C, HIV, or syphilis infection, confirmed by specific blood tests.
- People who have had a serious heart or blood vessel event in the 6 months before the first study dose, such as heart failure, heart attack, unstable chest pain, stroke, blood clots, or other listed cardiovascular conditions, or who have an abnormal heart rhythm measurement beyond certain thresholds.
- People who have an active infection requiring treatment throughout the body (such as severe pneumonia or blood infection) within 2 weeks before joining.
- People who have used corticosteroids (such as dexamethasone above a certain dose) for more than 3 consecutive days within 14 days before the first dose, or who are planned to use them during the study, or who are on immune-suppressing therapy for conditions such as severe radiation-related lung inflammation.
- Women who are pregnant or breastfeeding.
- People who have participated in another clinical trial and received treatment as part of that trial within 4 weeks before the first study dose.
- People whom the trial investigators judge to be unsuitable for other reasons.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
If this is close to home
This page includes language about advanced illness, prognosis, or palliative care, because that is how the trial's eligibility criteria are written. Seeing it set out plainly can land hard, whether it is about you or about someone you are caring for. You do not have to be at a crisis point to talk to someone.
- Griefline — grief and loss counselling, 9am to 6pm weekdays and midday to 6pm weekends (AEST/AEDT): 1300 845 745
- Carer Gateway — practical and emotional support if you are caring for someone, 8am to 5pm weekdays: 1800 422 737
- Canteen — for 12 to 25 year olds affected by cancer, their own or a family member's: 1800 945 215
- Palliative Care Australia — directory of palliative care services near you: palliativecare.org.au
- Lifeline — 24/7, for any kind of distress, at any hour the services above are closed: 13 11 14
Palliative care is not the same as giving up on treatment, and it is not only for the last weeks of life. It is symptom and comfort care that can run alongside active treatment, including a clinical trial.
Outside Australia? The numbers above are Australian and will not work from overseas. Find a Helpline is a free directory of support and crisis lines in over 130 countries, run by ThroughLine with the International Association for Suicide Prevention.
Voxsanity is not a counselling or medical service, and nothing on this page is medical advice. More Australian services are listed on our support lines page.
Contact this trial
Phone: 010-56315388
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Intracranial objective response rate (iORR) according to the RECIST 1.1.; Determining the Expansion Dose
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.